The antipsychotic trifluoperazine reduces marble-burying behavior in mice via D2 and 5-HT2A receptors: Implications for obsessive-compulsive disorder

Pharmacol Biochem Behav. 2018 Feb:165:9-13. doi: 10.1016/j.pbb.2017.12.006. Epub 2017 Dec 19.

Abstract

Trifluoperazine, a typical antipsychotic drug, not only antagonizes dopamine D2 receptors but also enhances serotonin 5-HT2 receptor-mediated behavior. Moreover, trifluoperazine suppresses human purinergic receptor P2X7 responses and calmodulin. However, the effect of trifluoperazine on marble-burying behavior, which has been considered an animal model of obsessive-compulsive disorder (OCD), has not been studied. Here, we examined the effect of trifluoperazine on marble-burying behavior in mice. Oral administration of paroxetine, a selective serotonin reuptake inhibitor, significantly reduced marble-burying behavior without affecting total locomotor activity. Similar results were obtained for trifluoperazine (3mg/kg). The D2 receptor agonist, quinpirole (0.03mg/kg, intraperitoneal [i.p.]), and 5-HT2A receptor antagonist, ketanserin (0.3mg/kg, i.p.), significantly counteracted this reduction of marble-burying behavior by trifluoperazine. These results show that trifluoperazine reduces marble-burying behavior via D2 and 5-HT2A receptors, and may be a useful drug for the treatment of OCD.

Keywords: Marble-burying behavior; Obsessive–compulsive disorder; Trifluoperazine.

MeSH terms

  • Animals
  • Antipsychotic Agents / metabolism
  • Antipsychotic Agents / pharmacology*
  • Antipsychotic Agents / therapeutic use
  • Behavior, Animal / drug effects*
  • Disease Models, Animal
  • Dopamine Agonists / pharmacology
  • Dopamine D2 Receptor Antagonists / metabolism
  • Dopamine D2 Receptor Antagonists / pharmacology*
  • Dopamine D2 Receptor Antagonists / therapeutic use
  • Ketanserin / pharmacology
  • Male
  • Mice, Inbred ICR
  • Motor Activity
  • Obsessive-Compulsive Disorder / drug therapy*
  • Paroxetine / pharmacology
  • Quinpirole / pharmacology
  • Receptor, Serotonin, 5-HT2A / metabolism
  • Receptors, Dopamine D2 / metabolism
  • Selective Serotonin Reuptake Inhibitors / pharmacology
  • Serotonin 5-HT2 Receptor Agonists / metabolism
  • Serotonin 5-HT2 Receptor Agonists / pharmacology*
  • Serotonin 5-HT2 Receptor Agonists / therapeutic use
  • Serotonin Antagonists / pharmacology
  • Trifluoperazine / metabolism
  • Trifluoperazine / pharmacology*
  • Trifluoperazine / therapeutic use

Substances

  • Antipsychotic Agents
  • Dopamine Agonists
  • Dopamine D2 Receptor Antagonists
  • Receptor, Serotonin, 5-HT2A
  • Receptors, Dopamine D2
  • Serotonin 5-HT2 Receptor Agonists
  • Serotonin Antagonists
  • Serotonin Uptake Inhibitors
  • Quinpirole
  • Trifluoperazine
  • Paroxetine
  • Ketanserin